Establishment of a novel renal immune prognostic index to predict clinical outcomes in renal cell cancer patients who received surgery

This multicenter retrospective study demonstrated that RIPI, integrating PALB, LYM, and IgM, provides robust and reproducible prognostic value in RCC patients. RIPI represents a reliable and clinically applicable tool for individualized risk stratification and outcome prediction.